Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Pemetrexed + Cisplatin as Induction vs Adjuvant Chemotherapy in Stage IB–II NSCLC
2005-003822-25Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pemetrexed and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Success of treatment delivery and Toxicity. Started Mar 2006; status: completed.
02
Drugs
pemetrexedcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-003822-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003822-25.